Differential DNA methylation has been linked to cancer mainly due to silencing of tumor-suppressor genes. Recent surge in research on epigenomics in cancer has produced tremendous amount of published literature, but till date there is no resource that collates all the information and represents it in an easily accessible and immediately useful form. In an effort to alleviate this problem, we propose a curated database MDDM, containing information about genes differentially methylated in cancer of various tissues. We present the database, its schema and sample queries on this database which cover the experimental methods, results in terms of sensitivity and specificity on particular tissues and cell lines. We also discuss the MDDM environment that is trying to pull information from various related resources. We propose a workflow and usage scenario for our MDDM environment to support a study for finding the role in gene regulation via DNA methyl binding proteins for breast cancer. In our usage scenario, we used the MSP primers reported in various studies to find the genomic area detected to be differentially methylated. These areas were searched for consensus sequence patterns for various methyl binding proteins to detect their potential binding and hence determine role in regulation of differential expression
Introduction
Epigenetics is a study of how the genotype unfolds into the phenotype without any visible changes in the genome. Epigenetic modifications including DNA methylation and histone modifications have been correlated to silencing of gene transcription. Cytosine methylation within the CG rich areas, also called CpG islands, has been most widely studied epigenetic modification in humans. Cancer epigenomics has been studied at small scale to predict methylation profiles in various cancers. Methylation of some gene promoter sequences have been found to be very closely correlated with cancer (e.g. GSTP1 in prostate cancer) but finding highly sensitive and specific epigenetic biomarkers needs a genome wide analysis.
Recent increased interest in epigenetics research has made available vast amount of knowledge on this topic. During the last one year, there were 2,500 articles published and many scientific meetings on epigenetics [3] . There have been many studies on individual genes however there is a need for a resource that can provide comprehensive access to information such as:
• The types of cancer epigenetics studies,
• Details about genes that are studied,
• The kind of experimental methods available,
• Results from each study for easier comparison,
• Research groups involved in cancer and researchers who have done this work,
• Cross correlating and linking information for comparison to various other studies such as transcriptomics, and proteomics related to the same genes.
In this paper we describe our Master Database of Differential Methylation (MDDM), a database and related environment that enables easy access to get an overview of the information mentioned above. It contains expert curated information about genes reported to be differentially methylated in various types of cancer. The database also contains the information about sequences that have been interrogated by various research groups. This is important if one wants to compare details from different studies which otherwise is a very tedious task.
Related Work
In this section we describe several efforts related to our MDDM database.
The Human Epigenome Project (HEP) (www.epigenome.org) aims to identify, describe and interpret genome-wide DNA methylation patterns of human genes in all major tissues. The latest release on 26th June 2006, covered 1.9 million CpG methylation values, obtained from the analysis of 2,524 amplicons across chromosomes 6, 20 and 22 in 43 samples derived from 12 different tissues [8] . All this effort can be very useful in comparing differential methylation in normal and cancer tissues. However, to date there is no resource that will enable this.
Online Mendelian Inheritance in Man (OMIM) is a database of human genes and genetic disorders containing ample textual information and references. While OMIM presents information about the hereditary and genetic factors involved in cancer, it does not present any epigenetic information that is revealed to date.
CancerGenes, a resource from MSKCC [9] is to simplify the process of gene selection and prioritization in large collaborative projects such as The Cancer Genome Atlas from NIH. This resource combines gene lists curated by experts with information from public databases.
However, in this whole multitude of tools we can not find immediately accessible curated knowledge about the link between DNA methylation and cancer. For this reason we decided to implement a comprehensive curated database for DNA methylation and cancer. In our first implementation we only incorporate genes related to breast, ovarian, cervical, endometrium, prostate and lung cancer. In this paper we will focus on developing our pilot database and writing queries that pertain to breast cancer.
Master Database of Differential Methylation (MDDM)
Master Database for Differential Methylaxtion in cancer (MDDM) is an attempt to collate available data on genes hypermethylated in cancer into an easily accessible resource. An extensive search is performed on PubMed for the articles reporting DNA methylation in various cancers. After careful reading and analysis, the experimental details on differentially methylated genes are collected from the articles and arranged in MDDM for easy retrieval of information as and when needed. The information collected includes the number of samples studied, reported sensitivity and specificity for each gene, the assay used, the genomic areas (promoter/gene) studied and their respective references. The entity-relationship (ER) model represents the database schema pictorially as shown in figure 1 .
As shown in the ER diagram, the database can be described broadly using nine entities and their corresponding relationships. The genes reported in literature have been listed in the GENE entity. Its attributes include the NCBI gene ID which forms the primary key, gene accession number, official gene name and its function. All the aliases of the reported genes have been listed in a separate entity (ALIAS).
Figure 1. Entity-relationship diagram for the Master Database of Differentially Methylated Genes in cancer (MDDM)
Usually there is more than one study that has reported differential methylation of each gene and the experimental details of these studies have been described in the EX-PERIMENT entity. Each tuple in EXPERIMENT entity has been given a unique ID. Its attributes include total number of samples, number of cases, controls, number of genes studied, the assay used, area of the gene studied and tissue studied e.g. breast cancer.
The histological subtypes are listed in SUBTYPE entity. The experimental ID together with histological subtype is used as primary key in this entity e.g. medullary breast carcinoma. The number of samples studied for each histological subtype, its description as case or control and the sensitivity and specificity of use of corresponding methylation marker in cancer detection are noted in this entity. The type of sample used (SAMPLE) is stored in a different entity which stores the sample details e.g. fresh frozen etc. and the number of each sample subtype used. If the samples used are cancer cell lines then the details of the cell lines are incorporated into another entity (CELLLINE). The attributes of this entity include name of the cell line, whether it was found to be positive or negative and the overall sensitivity of corresponding methylation marker in detecting cancerous change.
The corresponding references are stored in REFER-ENCE entity. The details about the year of publication, reference, title, journal and the lead author have been stored in this entity. The PubMed ID has been chosen as the primary key. The authors have been listed in another entity (AU-THOR). This entity includes all the details of the authors including the first name, middle name, last name, their location and their email contacts. Methylation-specific PCR is the most common assay used. The primers employed in each study using MSP are tabulated in the PRIMER entity. The attributes include the forward and reverse primers for both unmethylated and methylated reactions. These primers are sequence aligned with corresponding gene sequences and the in silico PCR product is also stored in the database.
This relational database design is very generic in the sense that a similar design may be extrapolated for other types of studies (e.g. gene expression).
Implementation and Querying MDDM
MDDM has been designed and implemented using Microsoft Access. The information for populating the database was manually retrieved by experts from the full articles. The information on genes was obtained from Entrez Gene. Our initial search was done on six cancers including breast, ovarian, cervical, endometrial, lung and prostate cancer. Information from more than 300 published articles has been collected and curated. In order to test and develop the appropriate applications, the database has been populated with breast cancer related information.
As part of their regular workflow, cancer biologists and clinical researchers working on epigenetics and cancer are interested in knowing various aspects and details reported in the existing literature. In this context, the database may be interrogated with a number of queries. These queries are broadly classified into three main categories as listed below. MDDM design helps to retrieve all such information easily.
Gene and article related queries 
List all the references that have worked with a primer sequence and vice versa.
Sample query: Find out the articles that have reported differential methylation of genes in breast cancer using the sequence "TATTGCGGAGTGCGGGTC" as forward primer for methylated reactions.
Overall statistics related queries
1. Find the cell-line which has been most extensively studied in a given cancer. Sample query: Find the cell-line most extensively studied in prostate cancer.
2. What are the most well studied and the least studied cancer? Sample query: Which cancer has been reported in the maximum number of studies?
3. Which gene has reported the highest differential methylation? Sample query: Retrieve the gene with maximum sensitivity and specificity.
4. Find out the maximum sensitivity or specificity achieved for a given gene in relation to cancer or vice versa. Sample query: What is the maximum sensitivity and specificity achieved by GSTP1 in any cancer?
Extending and Enabling MDDM

User access
For an easy user access webpage forms are necessary. These forms would be suited to all the above three categories of queries and that would help in easy retrieval of information. One sample webpage is shown in figure 2 . It shows results of a query in which a gene name is entered and the specificity and sensitivity range is specified. Similarly on the page methylation site (shown as tab), a genomic sequence is given and the pattern is matched with the PCR product sequences obtained by in silico PCR, stored in MDDM. The corresponding gene, the primers used, the cancer studied, the details of the references are retrieved by such a query. The results can be browsed one by one in such a form.
Automatic linking to other resources
In addition to its standalone value, as a highly curated resource, the current MDDM has the potential to be a unique resource for DNA methylation research when linked to other resources. Here we outline a few such useful links and applications. In figure 4 we present a high level view of the MDDM environment as envisioned to enable the following tasks. • Locating primer sequences on the human genome so that we know the target sequence that was interrogated by the experiment. This part involves automatic scripting and connection with ClustalW as well as in silico PCR.
• Automatically comparing found methylation sites with binding sites for methyl-binding proteins as well as transcription factors. For this purpose, the extension module will need access to all known binding sites for the respective proteins.
• Cross-checking if a differentially methylated sequence has been studied by the Epigenome project.
• Connection with the CancerGenes database to derive functional description, GO terms, InterPro descriptions, gene structure, protein length, transcript count, and experimentally determined transcript control regions
• In silico validation of experimentally derived genes. For a set of markers, we need to automatically cross link potential literature and all associated information about the methylated genes.
• Connection with newer tools such as DNA spectral analysis in order to see if there are any new patterns [6] . For example, one could study the zinc-finger like proteins among the reported genes and identify if there are any repetitive patterns with DNA spectral analysis.
Methyl binding protein study
Here we outline one potential usage scenario for MDDM in epigenetics research. The first step is to get all the genes for which the experimental assay was MSP. The partial result of breast cancer genes and references is tabulated in table 1 (due to space limitation). These 18 genes were reported to be differentially methylated using Methylationspecific PCR (MSP). The second step is to identify the candidate sequences interrogated for potential differential DNA methylation. The primers reported in literature are aligned with the respective sequences of the genes. The genomic sequences thus obtained on alignment were then used as primers for in silico PCR. The genes and the PCR products are listed in table 1.
For a cancer biologist the next step would be to find out if these genes have any methyl binding protein domain. This is potentially important the mechanism of cancer causation. Consensus sequences have been reported for various methyl binding proteins including Kaiso, MBD2-interacting zinc finger (MIZF) protein, MeCP2. TCCTGCNA was identified as the consensus sequence with a minimal core sequence of CTGCNA for Kaiso protein [5] . CGGACGTT with a conserved CGGAC core was reported as the consensus sequence for MIZF [16] . A run of [A/T ] ≥ 4 adjacent to methylated CpG was identified as binding site for MeCP2 [11] . The results obtained for consensus sequence pattern match in the candidate sequences (PCR products) in table 1 are listed in table 2.
Results
Many DNA binding sites for methyl binding proteins can be identified in the sequences derived from in silico PCR. The results show that the differentially methylated sequences on genes BRCA1, RASSF1, SFN, TWIST and TIMP3 have binding sequence for Kaiso protein. In this manner, a cancer biologist can formulate a hypothesis and a set of experiments to confirm this. Furthermore, the differentially methylated sequences on genes GSTP1. CDKN2A, CCND2, CDH1, ESR1, APC, MLH1 have binding for MIZF protein. Interestingly, the differentially methylated genes BRCA1, TWIST1, CCND2, RARB1, PTEN, TIMP3, MLH1, have a binding sequence for MeCP2.
Discussion
It is important to emphasize that this kind of workflow and analysis would have taken many days worth of work, and in our case, with the environment offered by MDDM this can take only a few minutes to formulate the question and come up with candidate sequences and plan next experiments. In this manner, DNA-protein interactions can be studied, postulating a new way to form gene networks and causality of epigenetic effects.
Currently MDDM covers limited number of articles (about 300). However, the structure is being tested so that this resources can be updated further to contain all the studied methylated regions in relationship to all known cancers. Although this is a very laborious task, we think that it is going to be very useful in a manner similar to CancerGenes for general knowledge about genes involved in cancer.
Conclusion
MDDM is a simple, robust and highly informative database for genes reported to be differentially methylated in cancer. The design incorporates all biologically relevant information to help biologists working in the cancer research and related areas. The information stored in MDDM can be used in detecting and evaluating methylation profile of various genes in cancer. The easy access to this information is important in order to compare details from different studies which otherwise is a very tedious task.
As the fast growing field of epigenetics and epigenomics is trying to explain the phenomena of DNA methylation, histone modifications and their relationship to disease, our resource will offer a way to make the connections among the reported literature. As discussed in Section 2, there are various resources which are not integrated to offer a productive environment. We started with the topic of DNA methylation and cancer and showed in this paper, that we can help in the workflow of a cancer biologist (just as an example) of querying the information about existing research, asking new biologically relevant questions and creating new hypothesis and new potential experimental plans in the case of differential methylation and methyl-binding proteins. As a next step, we want to integrate further information produced by the international consortia such as the Epigenome project in order to enable easy comparison with existing knowledge. 
Acknowledgements
